|
Squamous cell carcinoma of lung
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Glioblastoma Multiforme
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: AKT1: AKT serine/threonine kinase 1; ATG14: autophagy related 14; BECN1: Beclin 1; DDR1: discoidin domain receptor tyrosine kinase 1; ECM: extracellular matrix; GBM: glioblastoma multiforme; MTOR: mechanistic target of rapamycin kinase; PDGFR: platelet derived growth factor receptor; PIK3C3: phosphatidylinositol 3-kinase catalytic subunit type 3; RPTOR: regulatory associated protein of MTOR complex 1; RICTOR: RPTOR independent companion of MTOR complex 2.
|
31117874 |
2019 |
|
Idiopathic crescentic glomerulonephritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Crescentic glomerulonephritis was induced in DDR1-deficient mice and their wild-type (WT) littermates as controls, by injection of alloimmune sheep nephrotoxic serum (NTS).
|
22751008 |
2012 |
|
Alzheimer's Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
NEP can degrade amyloid beta peptides, and its mRNA and protein levels are known to be reduced in the brains of patients with Alzheimer's disease (AD), making the NEP gene a substantial candidate for an AD risk factor.
|
14739539 |
2004 |
|
Sarcoidosis, Pulmonary
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
DDR1 activation also induced NF-kappaB nuclear translocation in CD14-positive BALF cells of patients with deteriorated PS.
|
16166739 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
NEP protein overexpression was significantly more common in metastatic versus primary tumors (P = 0.002).
|
17207277 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NEP normally functions to inactivate peptides such as bombesin and endothelin-1, and potentiates the effects of the PTEN tumor suppressor via a direct protein-protein interaction.NEP loss contributes to PC progression.
|
17415380 |
2007 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
NEP-like endopeptidases and Alzheimer's disease [corrected].
|
20088804 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
DDR1 was expressed in 6 of 16 BAC (38%) and 95 of 155 invasive NSCLC (61%, p=0.065).
|
20596615 |
2010 |
|
Adenocarcinoma
|
0.310 |
AlteredExpression
|
group |
BEFREE |
DDR1 up-regulation tend to be more frequently observed in invasive adenocarcinoma (64%) compared to DDR1 expression in BAC (38%) (p=0.056).
|
20596615 |
2010 |
|
Bronchioloalveolar Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DDR1 up-regulation tend to be more frequently observed in invasive adenocarcinoma (64%) compared to DDR1 expression in BAC (38%) (p=0.056).
|
20596615 |
2010 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
NEP immunolabeling is reduced within cerebral blood vessels of Alzheimer's disease (AD) patients with cerebral amyloid angiopathy (CAA).
|
21382117 |
2011 |
|
Cerebral Amyloid Angiopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
NEP immunolabeling is reduced within cerebral blood vessels of Alzheimer's disease (AD) patients with cerebral amyloid angiopathy (CAA).
|
21382117 |
2011 |
|
AURAL ATRESIA, CONGENITAL
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NEP activity was reduced in CAA, in both controls and AD.
|
21382117 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DDR1 was expressed significantly more frequently in high-grade (79%) and advanced stage (77%) tumors compared to low-grade (50%) and early stage (43%) tumors.
|
21541037 |
2011 |
|
Malignant neoplasm of lung
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
DDR1 was expressed in a panel of human lung cancer cell lines, and high DDR1 levels in human lung tumors were associated with poor survival.
|
22223527 |
2012 |
|
Carcinoma of lung
|
0.150 |
AlteredExpression
|
disease |
BEFREE |
DDR1 was expressed in a panel of human lung cancer cell lines, and high DDR1 levels in human lung tumors were associated with poor survival.
|
22223527 |
2012 |
|
Primary malignant neoplasm of lung
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
DDR1 was expressed in a panel of human lung cancer cell lines, and high DDR1 levels in human lung tumors were associated with poor survival.
|
22223527 |
2012 |
|
Lung Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
DDR1 was expressed in a panel of human lung cancer cell lines, and high DDR1 levels in human lung tumors were associated with poor survival.
|
22223527 |
2012 |
|
Renal glomerular disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
DDR1 deletion protected NTS-treated mice against glomerular disease (proteinuria/creatininuria 5.5±1.1 vs. 13.2±0.8 g/mmol in WT, crescents 12±2 vs. 24±2% of glomeruli, urea 16±2 vs. 28±5 mM), hypertension (123±11 vs. 157±8 mmHg), and premature death (70 vs. 10% survival) (all P<0.05).
|
22751008 |
2012 |
|
Hypertensive disease
|
0.030 |
GeneticVariation
|
group |
BEFREE |
DDR1 deletion protected NTS-treated mice against glomerular disease (proteinuria/creatininuria 5.5±1.1 vs. 13.2±0.8 g/mmol in WT, crescents 12±2 vs. 24±2% of glomeruli, urea 16±2 vs. 28±5 mM), hypertension (123±11 vs. 157±8 mmHg), and premature death (70 vs. 10% survival) (all P<0.05).
|
22751008 |
2012 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
DDR1 promotes inflammation in atherosclerosis, lung fibrosis and kidney injury, while DDR2 contributes to osteoarthritis.
|
24361528 |
2014 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
DDR1 promotes inflammation in atherosclerosis, lung fibrosis and kidney injury, while DDR2 contributes to osteoarthritis.
|
24361528 |
2014 |
|
Degenerative polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
DDR1 promotes inflammation in atherosclerosis, lung fibrosis and kidney injury, while DDR2 contributes to osteoarthritis.
|
24361528 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DDR1 knockdown impaired tumor cell proliferation and migration in vitro and tumor growth in vivo.
|
25369402 |
2014 |